This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Illumina offers contract to customers for 12-year supply with guarantees of continued supply, no price increases

( April 1, 2021, 13:16 GMT | Official Statement) -- MLex Summary: To allay concerns regarding its acquisition of Grail, Illumina said it is offering new and existing US oncology customers a 12-year supply contract for its sequencing products and support services, a guarantee that it won't discontinue any of the sequencing products supplied under the offer as long as the customer continues to buy the product, and a guarantee of no price increases for the sequencing products covered, along with other provisions. The company said that among the concerns it is addressing is the fear that it would increase sequencing prices or withhold access to Illumina’s latest innovations, creating a disadvantage for Grail competitors.Statement and document follow below:...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections